ribonuclease A family member 6Genealiases: RAD1 · RNS6 · RNasek6
Q-omics provides the consensus-scored RNASE6 profile across patient tissues and cancer cell-line models. RNASE6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNASE6 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RNASE6 RNA expression shows 21,405 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where RNASE6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASE6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASE6 survival associations across molecular data types. RNASE6 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASE6 RNA expression–survival associations across cancer types. High RNASE6 expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, SKCM, CESC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RNASE6 RNA expression.
This table summarizes RNASE6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RNASE6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASE6 shows lower tumor expression in LUSC, COAD, BLCA and UCEC and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher RNASE6 RNA expression in tumor versus normal tissue (log2 FC = +2.148, t-test p < 0.001).
This table shows molecular features associated with RNASE6 in patient tissues and cancer cell lines. In patient samples, RNASE6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASE6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
